Adaptive Biotechnologies and NeoGenomics have partnered to expand access to personalised disease monitoring for blood cancer patients.
The multi-year collaboration focuses on improving minimal residual disease (MRD) monitoring options for blood cancer patients.
The collaboration combines Adaptive Biotechnologies’ expertise in biotechnology and NeoGenomics’ oncology testing services.
Adaptive Biotechnologies’ clonoSEQ is said to be the first US Food and Drug Administration (FDA)-cleared next-generation sequencing (NGS)-based test for detecting MRD in lymphoid cancers. Additionally, clonoSEQ is CE-marked in the European Union (EU).
Nasdaq-listed NeoGenomics offers COMPASS and CHART, personalised services for complex blood cancers.
The integration of clonoSEQ with COMPASS and CHART will allow oncologists to deliver personalised treatment plans.
This partnership enhances risk assessment and provides real-time insights into disease progression with advanced MRD testing.
Adaptive Biotechnologies CEO and co-founder Chad Robins said: “Our partnership with NeoGenomics reflects our shared commitment to empowering oncologists and pathologists to deliver the highest quality patient care.
“As a leader in oncology testing with an extensive menu of precision oncology offerings, NeoGenomics is a natural partner for us.”
Under the exclusive agreement, COMPASS evaluations for multiple myeloma (MM), B-cell acute lymphoblastic leukaemia (B-ALL), chronic lymphocytic leukaemia (CLL), and diffuse large B-cell lymphoma (DLBCL) will now include clonoSEQ Clonality (ID) testing.
This identifies patient-specific DNA sequences at diagnosis, enabling MRD tracking with clonoSEQ.
CHART assessments for these patients will also integrate clonoSEQ MRD testing throughout their care.
Testing will be conducted by Adaptive Biotechnologies’ lab in Seattle.
Clinicians using NeoGenomics’ COMPASS to diagnose blood cancers can now identify DNA sequences needed to track a patient’s cancer, ensuring access to clonoSEQ MRD insights throughout treatment.
This enhances patients’ chances of qualifying for clinical trials that rely on clonoSEQ for therapy guidance.
With CHART, clinicians can easily conduct ongoing MRD testing, enabling disease monitoring and helping those less familiar with MRD to use results at the right medical timepoints.
NeoGenomics CEO Chris Smith said: “MRD testing is widely recognised as an integral part of blood cancer patient care, serving not only as a powerful prognostic tool but also guiding clinical decision-making.
“NeoGenomics is proud to offer our customers access to clonoSEQ, the gold standard for clinical MRD monitoring.”
Following this partnership, Adaptive Biotechnologies and NeoGenomics will begin implementing the necessary commercial and operational infrastructure to support the partnership.
The companies plan to launch cross-promotional efforts later this year. Specific financial terms of the agreement have not been disclosed.
